Sheet 1 of 11 Atty. Docket No. Serial No. 575-55873-C/ 10/666,513 Form PTO-14 Department of JPW/AJM/AAB Commerce Applicant(s) Patent and Trademark Office Ann Marie Schmidt, et al. Filing Date **Group Art Unit** INFORMATION DISCLOSURE CITATION September 19, 2003 (Use several sheets if necessary) **U.S. PATENT DOCUMENTS** Filing Date Name Class Subclass **Examiner Document Number** Date If Appropriate Initials Ulrich, et al. 11/18/97 8 8 6 5 3 5 1/26/99 Morser, et al. 4 0 1 8 8 6 Hitomi, et al. 9 6 8 3 2 11/2/99 FOREIGN PATENT DOCUMENTS Translation Country Class **Document Number** Date Subclass Yes No 1 10/23/97 PCT WO WO 9 7 3 9 1 5 10/23/97 PCT OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412; Borchelt, D. R., et al. (1996). Familial Alzheimer's Diseaselinked presenilin 1 variants elevate AB1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013; Brett, J., et al. (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6):1699-1712; Brownlee, M. (1992). Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15(12):1835-1842; Cai, X-D., et al. (1993). Release of excess amyloid β protein

EXAMINER DATE CONSIDERED
-8:19.04

\*EXXMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

from a mutant amyloid  $\beta$  protein precursor. Science 259: 514-516; Citron, M., et al. (1997). Mutant presentions of Alzheimer's Disease increase production of 42-residue amyloid  $\beta$ -protein in both transfected cells and transgenic mice. Nature Medicine 3(1):

Sheet 2 of 11

Form PTO-1449 U.S. epartment of Commerce ent and Trademark Office

Atty. Docket No. 575-55873-C/ JPW/AJM/AAB Serial No. 10/666,513

Applicant(s)

Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date September 19, 2003 **Group Art Unit** 

# U.S. PATENT DOCUMENTS

Examiner Initials	Document Number					er	Date	i	Name	Class	Subclass	Filing Date If Appropriate
_			L									
			L	_								
				<u>.</u>								
			Г									
	1		Γ					<del> </del>				

# FOREIGN PATENT DOCUMENTS

													Trans	lation
Examiner Initials	 D	ocu	m	ent	Nu	mb	er	Date	Name		Class	Subclass	Yes	No
			L		L				 					
			L		_									
						L.								
			L				Ш		 					
								ı						

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Dell'Angelica, E.C., et al. (1994). Primary structure and
	binding properties of calgranulin C, a novel S100-like
<i>[  </i>	calcium-binding protein from pig granulocytes. J. Biol. Chem.
10/M	269: 28929-28936;
	Fahey, T., et al. (1991). Diabetes impairs the late inflammatory
	response to wound healing. J. Surg. Res. 50: 308-313;
	Fu, M-X., et al. (1996). The advanced glycation end product,
	N°-(carboxymethyl)lysine, is a product of both lipid peroxidation
	and glycoxidation reactions. J. Biol. Chem. 271: 9982-9986;
	Giardino, I., et al. (1994). Nonenzymatic glycosylation in vitro
	and in bovine endothelial cells alters basic fibroblast growth
	factor activity. J. Clin. Invest. 94: 110-117;
	Gibbons, G. H. and V. J. Dzau. (1996). Molecular therapies for
	vascular diseases. Science 272: 689-693.;
	Hofmann, M. A., et al. (1999). RAGE mediates a novel
	proinflammatory axis: a central cell surface receptor for

EXAMINER /

DATE CONSIDERED

s100/calgranulin polypeptides. Cell 97:889-901;

8.19.00

Sheet 3 of 11 Atty. Docket No. Serial No. 575-55873-C/ 10/666,513 Form PTO-1449 partment of Commerce JPW/AJM/AAB tent and Trademark Office Applicant(s) Ann Marie Schmidt, et al. INFORMATION DISCLOSURE CITATION Group Art Unit Filing Date (Use several sheets if necessary) September 19, 2003 U.S. PATENT DOCUMENTS Examiner 'Name Class Subclass Filing Date **Document Number** Date Initials If Appropriate FOREIGN PATENT DOCUMENTS Translation Examiner **Document Number** Date Name Class Subclass Yes No Initials OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Hori, O., et al. (1995). The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin J. Biol. Chem. 270: 25752-25761; Khoury, J. E., et al., (1994). Macrophages adhere glucose-modified basement membrane collagen IV their scavenger receptors. J. Biol. Chem. 269: 10197-10200; Kuo, Y-M., et al. (1996). Water-soluble  $A\beta$  (N-40, oligomers in normal and Alzheimer Disease brains. J. Biol. Chem. 271(8): 4077-4081; Lander, H. M., et al. (1997). Activation of the receptor for advanced glycation end products triggers a p21<sup>ras</sup> dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272: 17810-17814; Ledesma, M. D., et al. (1994). Analysis of microtubuleassociated protein tau glycation in paired helical filaments. J.

Biol. Chem. 269 (34):21614-21619;

EXAMINER

Biol. Chem. 269 (34):21614-21619;

DATE CONSIDERED

8-19-04

Atty. Docket No. Serial No. 575-55873-C/ 10/666,513 Form PTO-1449 partment of Commerce JPW/AJM/AAB Patent and Trademark Office Applicant(s) Ann Marie Schmidt, et al. INFORMATION DISCLOSURE CITATION Filing Date **Group Art Unit** (Use several sheets if necessary) September 19, 2003 U.S. PATENT DOCUMENTS Examiner Name Class Subclass Filing Date **Document Number** Date Initials If Appropriate FOREIGN PATENT DOCUMENTS Translation Examiner **Document Number** Date Name Class Subclass Yes No Initials OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Li, J. and A.M. Schmidt (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 272: 16498-16506; Lorenzo, A. and B.A. Yanker (1994).  $\beta$ -amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Nat. Acad. Sci. USA 91: 12243-12247; Mattson, M. P. and Y. Goodman (1995). Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 676: 219-224; Miyata, T., et al. (1996). The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-eta 2 Microglobulin with human mononuclear phagocytes via an

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

oxidant-sensitive pathway. J. Clin. Invest. 98: 1088-1094;

Sheet 5 of 11 Atty. Docket No. Serial No. 575-55873-C/ 10/666,513 Form PTO-1449 epartment of Commerce JPW/AJM/AAB atent and Trademark Office Applicant(s) Ann Marie Schmidt, et al. INFORMATION DISCLOSURE CITATION Filing Date Group Art Unit (Use several sheets if necessary) September 19, 2003 **U.S. PATENT DOCUMENTS** Examiner Name Class Subclass Filing Date **Document Number** Date Initials If Appropriate FOREIGN PATENT DOCUMENTS Translation Examiner **Document Number** Date Class Name Subclass Yes Initials OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Nakamura, Y., et al. (1993). Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143(6): 1649-1656; Neeper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267: 14998-15004; Palinski, W., et al. (1995). Immunological evidence for presence advanced glycosylation end of products in atherosclerotic lesions of euglycemic rabbits. Arterioscl. Thromb. and Vasc. Biol. 15(5): 571-582; Park, L., et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 4: 1025-1031; Park, L., et al. (1997). A murine model of accelerated diabetic suppression by soluble receptor for advanced atherosclerosis: glycation endproducts. Circulation Supplement. Abstract 3079; EXAMINER/ DATE CONSIDERED

Form PTO-1449	U.S. Department of Commerce
INFORMA'	TION DISCLOSURE CITATION

Atty. Docket No. 575-55873-C/ JPW/AJM/AAB

Serial No. 10/666,513

Applicant(s)

Ann Marie Schmidt, et al.

#### N (Use several sheets if necessary)

Filing Date September 19, 2003 Group Art Unit

· · · · · · · · · · · · · · · · · · ·									U.S.	PATENT DOCUM	IENTS			
Examiner Initials		D	ocu	mė	ent	Nu	mb	er	Date	Name	Class	Subclass	Filing I	Date ropriate
														_
						Γ								
					1	Т							İ	
					T	T		-		•			1	
		7			$\dagger$	T	$\dagger$				<del> </del>	<b>\</b>	1	
		_			+-	†	$\dagger$							
	$\dashv$	+	-	$\vdash$	$\dagger$	$\vdash$	+	-	<del></del>					
	1					Л	<u></u> -	]	FOREIC	ON PATENT DOC	UMENTS			
													Trans	lation
Examiner Initials		Do	ocu	me	ent	Nu	mb	er	Date	Name	Class	Subclass	Yes	No
		$\perp$					_							

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Reddy, S., et al. (1995). $N^{\epsilon}$ -(Carboxymethyl)lysine is a dominant
	advanced glycation end product (AGE) antigen in tissue proteins.
	Biochemistry 34: 10872-10878;
	Renard, C., et al. (1997). Recombinant advanced glycation end
1 / 1	product receptor pharmacokinetics in normal and diabetic rats.
	Mol. Pharm. 52: 54-62;
	Ritthaler, U., et al. (1995). Expression of receptors for
	advanced glycation end products in peripheral occlusive vascular
	disease, Am. J. Pathol. 146: 688-694;
	Roher, A. E., et al. (1996). Morphology and toxicity of Aβ-(1-
	42) dimer derived from neuritic and vascular amyloid deposits of
	Alzheimer's Disease. J. Biol. Chem. 271(34): 20631-20635;
	Schleicher, E. D., et al. (1997). Increased accumulation of the
	glycoxidation product $N^{\epsilon}$ -(carboxymethyl)lysine in human tissues
<b>V</b> //	in diabetes and aging. J. Clin. Invest. 99: 457-468;

DATE CONSIDERED

Sheet 7 of 11

Form PTO-1449

artment of Commerce f and Trademark Office

Atty. Docket No. 575-55873-C/ JPW/AJM/AAB

Serial No. 10/666,513

Applicant(s)

Ann Marie Schmidt, et al.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Filing Date September 19, 2003 Group Art Unit

# U.S. PATENT DOCUMENTS

Examiner Initials	D	ocu	me	nti	Nur	nbo	er	Date	Name	Class	Subclass	Filing Date If Appropriate
			L							1		
						L		•				
	 c											
				_	·				 			

#### FOREIGN PATENT DOCUMENTS

		_							_				Trans	lation
Examiner Initials		D	ocu	ıme	ent	Nu	mb	er	Date	Name	Class	Subclass	Yes	No
			ļ	_							 			
				↓	<u> </u>	<u> </u>					 		-	
		_		-		L					 		ļ	
				<del> </del>		-					 			
	-			+		├		Н			 		ļ	
			_	t	-	┢		Н			 7		1	

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	THER DOCUMENTS (Including Author, Thie, Date, Fertilient Fages, Etc.)
	Schmidt, A. M., et al. (1995). Advanced glycation endproducts
1	interacting with their endothelial receptor induce expression of
1/1/1	vascular cell adhesion molecule-1 (VCAM-1) in cultured human
<u> </u>	endothelial cells and in mice. J. Clin. Invest. 96: 1395-1403;
l" /	Schmidt, A. M., et al. (1994). Receptor for advanced glycation
1 /	endproducts (AGEs) has a central role in vessel wall interactions
	and gene activation in response to circulating AGE proteins.
	Proc. Nat'l Acad. Sci. USA 91: 8807-8811;
.	Schmidt, A. M., et al. (1992). Isolation and characterization of
	two binding proteins for advanced glycosylation end products from
	bovine lung which are present on the endothelial cell surface.
	J. Biol. Chem. 267: 14987-14997;
	Schmidt, A. M., et al. (1994). Cellular receptors for advanced
	glycation end products. Arterioscler. Thromb. 14:1521-1528;
N	Schmidt, A. M., et al. (1995). The dark side of glucose. (News
'	and Views) Nature Medicine 1. 1002-1004.

DATE CONSIDERED

				F	3						Sile			
Form PT	'O-1	449	)		(A)	P:	ADE .S.	Departi	ment of Commerce Frademark Office	Atty. Docke 575-55873-0 JPW/AJM/	C/ . AAB		al No. 66,513	
								•		Applicant(s Ann Marie	•	al.		
IN	FO							OSURI	E CITATION ssary)	Filing Date September	19 2003	Gro	up Art	Unit .
										<u></u>				
	Γ.							U.S.	PATENT DOCUMI	ENTS	<del></del>			
Examiner Initials		Do	cun	nen	t Ni	ımb	er	Date	Name	Class	Subclas		Filing If App	Date ropriate
0		H	$\dashv$	}	-	-	┝				-			
	-	$\vdash$	$\dashv$	$\dashv$	+	+	-							
<u>:</u>		$\vdash$	+	$\dashv$	+	╁	╁	-			<u> </u>			<del></del>
		$\dagger \dagger$	7	$\dagger$	$\dagger$									-
		$\Box$	1	7	1	$\dagger$	T							
	,							FOREIC	ON PATENT DOCU	MENTS				
Examiner		Do	en n	nen	t Nu	ımb	er	Date	Name	Class	Subclas			slation
Initials		00						Date		Class	Subcias	,3	Yes	No
		-	+	+	+	-	$\vdash$		•					
			+	+	-	+-	$\vdash$						•	
			$\top$	$\perp$										
		-	+	+	+	$\vdash$	L					_		
			+	+	+	$\vdash$	$\vdash$							! !
	O	THE	R	DC	CU	JМ	EN	ITS (Inc	luding Author, Title	, Date, Peri	inent Pag	es, E	tc.)	I
11		ph	ag	oc;	yte	m	ig	ration	al. (1993). Re by cell surface cts. J. Clin. I	-binding	protein	s fo	or ad	uclear vanced
4/		Sc	hm	id	t,	Α.	]	M., et	al. (1997).	The V-do	main of	re	cepto	
									endproducts (RAG erapy of diabet					GEs: a
		Su	pp.	lei	men	t	96	:#194,	p. I-37;	-				
-		Sc fo	hm. r	id ad	t, Ivai	A. nce	M d	., et a	al. (1994). The tion end produc	e endothel ts consis	lial cel sts of	l bi	ndin omple	g site
		in	te	gra	al	me	mb	rane p	rotein and a la	ctoferrin	-like p	olyp	epti	de. J.
									32-9888; 1. (1998). RAGE	: a rece	ptor wit	ch a	tas	te for
		mu	lt.	ip.	le	Ļi	ga	nds and	d varied pathoph					
		_						1-63; al.	(1989). Structu	re elucid	ation o	of a	sen	escene
		cr	os	s-:	lin	k	£	rom h	uman extracellang process. J. B	ular mat	rix; i	mpli	cati	on of
EXAMINE	R	U.							DATE CONSIDERED					· · · · · · · · · · · · · · · · · · ·
*EXAMINE	R:	Initia	ıl if	cita	ation	con	sid	ered, whet	ther or not citation is in c	onformance wi	ith MPEP 60	)9: Dr	aw line	through
citation if no	ot in	conf	orm	anc	e ar	ıd ne	ot c	onsidered.	Include copy of this for	m with next co	mmunicatio	n to ap	plican	t.

JAN 0 9 2004 8 3

Form PTO-1449

U.S. Declarate of Commerce Patent and Trademark Office Atty. Docket No. 575-55873-C/ JPW/AJM/AAB Serial No. 10/666,513

Applicant(s)

Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date September 19, 2003 Group Art Unit

#### U.S. PATENT DOCUMENTS

Examiner Initials		Doci	ume	nt i	Nun	nbe	r	Date		Name		Class		Subclass	Filing Date If Appropriate
			_						ļ						
	$\perp$		_										<u>.</u>		
		-	<u> </u>								•				
		$\perp$	<u> </u>						ļ						
	_		_							•					
		1_	<u> </u>						ļ						
İ									1	•					

#### FOREIGN PATENT DOCUMENTS

													Trans	lation
Examiner Initials		D	ocu	me	enti	Nu	mb	er	Date	Name	Class	Subclass	Yes	No
	`													
						Γ	<u> </u>							
		-						$\vdash$			-		-	

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Ar.	Soulis, T., et al. (1997). Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40: 619-628;
	Turner, R.S., et al. (1997). Amyloids $\beta_{40}$ and $\beta_{42}$ are generated intracellularly in cultured human neurons and their secretion increases with maturation. J. Biol. Chem. 271(15): 8966-8970;
	Vitek, M.P., et al. (1994). Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Nat'l Acad. Sci. USA 91: 4766-4770;
	Vlassara, H., et al. (1995). Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Molec. Med. 1: 634-646;
	Vlassara, H., et al. (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70: 138-151;

EXAMINER

DATE CONSIDERED

811904

Sheet 10 of 11 Atty. Docket No. Serial No. 575-55873-C/ 10/666,513 U.S. Depa Form PTO-1449 JPW/AJM/AAB Patent and Name Applicant(s) Ann Marie Schmidt, et al. INFORMATION DISCLOSURE CITATION Group Art Unit Filing Date (Use several sheets if necessary) September 19, 2003 **U.S. PATENT DOCUMENTS** Examiner Name Class Subclass Filing Date **Document Number** Date Initials If Appropriate FOREIGN PATENT DOCUMENTS Translation Examiner **Document Number** Date Name Class Subclass Yes No Initials OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Vlassara, H., et al. (1995). Identification of Galectin-3 as a high affinity binding protein for advanced glycation products. Arterisocler. Thromb. 14:1521-1528; Wautier, J.-L., et al. (1996). Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97: 238-243; J.-L., et al. (1996).Interaction erythrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

94(8): #4139;

intermediates and cellular dysfunction. Circulation Supplement

Wu J., et al. (1997). The soluble receptor for advanced glycation endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice. Plastic Surg. Res. Council Abstract #77, p. 43;

								E.	Ä		Snee	t 11	01 11	
Form PT						Departr	ment of Commerce				Serial No. 10/666,513			
										Applicant(s) Ann Marie Schmidt, et al.				
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									Filing Date September 19, 2003			Group Art Unit		
								U.S.	PATENT DOCUMI	ENTS		I		
Examiner Initials		Document Number					er	Date	Name	Class Subcl		Filing Date If Appropriate		
			╁	-	_	ļ	_						· -	
	_		╁	-	_	╁	_							
		+	╁		6	╁							· · · · · · · · · · · · · · · · · · ·	
											,			
			<u> </u>	-		<u> </u>	_							
	<u> </u>		J	L		Ŀ		FORFIC	 GN PATENT DOCU	IMENTS				
	FOREIGN FATENI DOCC											Translation		
Examiner Initials		Doc	ocument Number					Date .	Name	Class	Subclass		Yes	No
		+	H											
					·									
		-	H				_				-	$\dashv$		
		-	$\dagger\dagger$								<del> </del>	-	· <u>.</u>	
	Ol								luding Author, Title		_		•	
1									(1994). Enhanc advanced glyca					
///		rec	ep	to	rs	/b:	in	ding p	roteins. J. Biol	. Chem. 2	69: 988	9-9	897;	
	·	Yan	•						il. (1996). RA zheimer's diseas					eptide
	-	Yan		s					al. (1997). An					r for
						g	ly	cation	endproduct :	interactio	on elic	cit:	s ne	uronal
		expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Nat'l Acad.												
								-5301;						
•								•						
										· · · · · · · · · · · · · · · · · · ·				

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED